Adimab
North America, New Hampshire, United States, Lebanon
Description
Adimab is an antibody discovery and optimization platform, developing full-length human Immunoglobulin Gs.
Investor Profile
Adimab has backed more than 2 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 1 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series A, Series C rounds (top funding stages).
- Majority of deals are located in United States.
- Strong thematic focus on Biotechnology, Pharmaceutical, Therapeutics.
Stage Focus
- Series A (50%)
- Series C (50%)
Country Focus
- United States (100%)
Industry Focus
- Biotechnology
- Pharmaceutical
- Therapeutics
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
